Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
about
Tyrosine phosphorylation of the orphan receptor ESDN/DCBLD2 serves as a scaffold for the signaling adaptor CrkLThe molecular rationale of Src inhibition in colorectal carcinomasPhosphorylation-mediated regulation of alternative splicing in cancerStructural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic MacrocyclesPELP1 suppression inhibits colorectal cancer through c-Src downregulationA Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.Locking the active conformation of c-Src kinase through the phosphorylation of the activation loopNeutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.A novel role for ezrin in breast cancer angio/lymphangiogenesis.Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.Actin stress fiber organization promotes cell stiffening and proliferation of pre-invasive breast cancer cells.Identification of potent Yes1 kinase inhibitors using a library screening approach.Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell linesSelective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targetsCombined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitmentComparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasionDiacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src.Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasionCD147 promotes Src-dependent activation of Rac1 signaling through STAT3/DOCK8 during the motility of hepatocellular carcinoma cells.Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neuronsCyr61 as mediator of Src signaling in triple negative breast cancer cells.Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesionNovel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patientsNovel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib.Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.c-Src/Cav1-dependent activation of the EGFR by Dsg2Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cellsIntegrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
P2860
Q24295091-DAE9ADE5-19FE-4AAC-9977-96ED02CE60F5Q26853018-BBD6D1FA-AEF5-47C0-993C-C2158DE14019Q27009883-B9011BE5-EB8E-4B4D-A3D6-1CB77FFA1DE7Q27727987-265B32CC-7996-4BB0-8856-E0266797518FQ28242802-EE5A8F29-2086-4A55-BCCE-F95581CC4CF9Q30009284-3063F266-1706-43FF-A851-7C9A7303FEE7Q30009548-3A32E802-44B3-4D97-8352-3CA40029BF16Q30361219-195701AD-3866-4100-AC3D-C50B84204DDEQ30617722-D235AE28-0064-4868-8A27-EA95205105A9Q30655673-BD1BEEF0-B34C-45A9-BC38-2BE93C2F4DF1Q30852504-FAE5671C-F407-4D34-A6F9-B6C2EFE50CD4Q31119738-19D78EFE-4375-416C-9B88-C1CEBDF9C2A0Q31159325-18CA92C1-4C7C-41D8-9B8B-CEFF89A896BBQ33637065-E5DEACD7-846B-4A03-9096-2BBCD7E0191EQ33709279-17AD168D-EF61-4D04-B051-F8AE4497D56BQ34023663-88AABBB3-A720-4563-9D10-8113318FC6E5Q34100838-18878D9F-4B09-4870-A2B8-058EB2FA0585Q34230548-345AED58-97E1-444D-8197-DED99883768FQ34309915-324F0578-5846-41F4-9C02-B7C05C79B728Q34473662-180AF124-6BED-4A8E-A831-A86E49643F60Q34654588-4C5B012F-AB9E-46D9-853D-95A658DAC3D6Q34731436-E884A57C-39E3-48B7-8F6B-31413113F7F5Q35238440-3C033C24-7934-4059-AD6B-7CA2E939BCF4Q35677049-936648F6-AC97-4C11-85D3-02EC32160D0EQ35684016-5275F4AE-469C-477A-9E03-D2F3D4124DBBQ35955373-E977B8BD-3EF8-4698-B0A9-30DEF3EA9FDAQ35987339-AF7489E8-258A-442E-9E95-A19D49C4B343Q36562098-FD35A345-6E20-49EA-8087-3924CAC47D1EQ36732781-DBFD7EDE-CB50-4320-8AE0-0E866220D7D3Q36853436-6B41DC94-BB54-4311-9748-88DCE1E3A354Q37116160-EDACB928-A043-4931-8CBF-7E78A58C44FCQ37205970-464F7932-135C-4736-A778-C71C9376BE17Q37230631-EA19E28B-35A8-46F8-AF13-B2D060C47123Q37412022-A90E9C29-B420-4A96-89C4-1BC35D8C6B2CQ37418248-17850952-5ED0-4C0A-B7FA-F9FE198405E2Q37437211-0675B61F-4CCB-4196-9C71-AA9B43779D44Q37494943-1CAA4D65-1FAD-4D85-B976-F91C55A6DAFDQ37591464-5C460928-6D64-4F53-84CE-8169B8B4163EQ37605645-1223AAE9-B27B-4D82-9404-1B6DEEFD5E60Q37688123-D92E95EA-1E71-4AEA-850D-3C59C5809139
P2860
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@ast
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@en
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@nl
type
label
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@ast
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@en
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@nl
prefLabel
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@ast
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@en
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@nl
P2860
P3181
P1476
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
@en
P2093
P2860
P304
P3181
P356
10.1016/J.TIPS.2011.11.002
P407
P50
P577
2011-12-09T00:00:00Z